<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>FDA review on FinanClub</title>
    <link>https://finan.club/tags/fda-review/</link>
    <description>Recent content in FDA review on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sat, 23 Mar 2024 09:01:55 +0000</lastBuildDate><atom:link href="https://finan.club/tags/fda-review/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>CBAY</title>
      <link>https://finan.club/us/cbay/</link>
      <pubDate>Sat, 23 Mar 2024 09:01:55 +0000</pubDate>
      
      <guid>https://finan.club/us/cbay/</guid>
      <description>score:-158
Chances: Gilead Sciences, Inc. has completed the acquisition of CymaBay Therapeutics, Inc. for approximately $4.3 billion, indicating positive returns for CBAY shareholders. Risks: The acquisition may result in changes in CymaBay&amp;rsquo;s product pipeline and research direction, leading to uncertainty for investors. The acceptance of seladelpar NDA for priority review by the U.</description>
    </item>
    
  </channel>
</rss>
